HHSN2710001: SRI International, Inc.: "NIMH Toxicological Evaluation of Novel Ligands program" from 9/1/2014-8/31/2015. The amount of $59,470.00

NIMH新型配体毒理学评价计划的目的是加速新型配体在人类成像中的发现、开发和应用。该计划还将 促进发现和开发用于临床研究的新型精神活性剂，并作为治疗精神障碍的潜在治疗剂。这一举措将提供一个关键的 补充NIMH现有的精神活性药物筛选计划的资源，用于在受体，通道和转运蛋白的结合试验中对新型化合物进行药理学表征。 中枢神经系统和生物化学测定以评估功能活性。新配体计划的毒理学评价也将补充 加速开发用于人类研究的新型PET和SPECT脑成像配体的倡议。这些努力 将协调各项活动，以建立一个管道，迅速和具有成本效益地开发用于精神障碍临床研究的新型配体。

The purpose of the NIMH Toxicological Evaluation of Novel Ligands Program is to accelerate the discovery, development, and application of novel ligands for imaging in humans. The program will also facilitate the discovery and development of novel psychoactive agents for clinical research and as potential therapeutic agents for the treatment of mental disorders. This initiative will provide a critical resource that complements NIMH’s existing Psychoactive Drug Screening Program for pharmacological characterization of novel compounds in binding assays for receptors, channels, and transporters in the central nervous system and in biochemical assays to assess functional activity. The Toxicological Evaluation of Novel Ligands Program will also complement the initiative to accelerate the Development of Novel PET and SPECT Ligands for Brain Imaging for use in human studies. Efforts of these activities will be coordinated to establish a pipeline for the rapid and cost-effective development of novel ligands for clinical studies of mental disorders.